← USPTO Patent Grants

3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression

Grant US12590086B2 Kind: B2 Mar 31, 2026

Assignee

Takeda Pharmaceutical Company Limited

Inventors

Tomoaki Hasui, Satoshi Mikami, Toru Yamashita, Shinji Nakamura, Shinji Morimoto, Toshihiro Imaeda, Kazuaki Takami, Masaki Daini, Hiroyuki Kakei, Minoru Nakamura, Fumie Yamaguchi, Chunxiang Wang, Sachie Takashima, Makoto Kamata, Yuya Oguro, Shuhei Ikeda

Abstract

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

CPC Classifications

C07D 413/14 C07D 401/14 C07D 405/14

Filing Date

2021-05-20

Application No.

17999514

Claims

27